Cardax expands market reach with HECL partnership for ZanthoSyn distribution in Greater China

Cardax, a pioneering pharmaceutical company based in Hawaii, has announced a significant partnership with Hong Kong-based Health Elite Club (HECL) to distribute ZanthoSyn, its premier astaxanthin dietary supplement. The agreement covers key Asian markets including China, Macau, Taiwan, and Hong Kong, and targets affluent and high-profile Chinese consumers through HECL’s exclusive, membership-based club.

Strategic Distribution and Market Expansion

Under the terms of the purchase agreement, HECL will distribute ZanthoSyn under its house brand, Puerfons, while ensuring that all packaging and marketing materials prominently feature the ZanthoSyn brand. This strategic move is aimed at leveraging HECL’s established network and e-commerce strength to maximize the product’s reach and impact in these critical markets.

David G. Watumull, President and CEO of Cardax, expressed enthusiasm about the partnership: “We are very pleased to be working with such a highly entrepreneurial company as HECL. HECL’s distribution model looks quite promising and their principals are highly credible. We look forward to building our relationship as HECL’s business grows in China.”

Addressing Health Concerns in a Growing Market

The partnership comes at a crucial time, as China faces increasing health challenges related to industrialization and pollution. ZanthoSyn’s anti-inflammatory properties are particularly relevant, offering potential health benefits linked to longevity, which is a growing concern among China’s rapidly aging population.

Li Wu, Chairman of HECL, highlighted the significance of the agreement: “U.S. products with scientific and manufacturing credibility such as ZanthoSyn are highly prized in China and we are excited to bring Puerfons ZanthoSyn into this important market.”

Regulatory and Product Development

HECL will manage all regulatory approvals required for distribution in the agreed territories, ensuring compliance and smooth market entry. Additionally, Cardax is developing another product, CDX-085, a more concentrated form of the astaxanthin supplement, which indicates the company’s ongoing commitment to innovation and market expansion.

The announcement also included news that ZanthoSyn can now be purchased at GNC stores in Guam, further widening its availability and consumer access.